Cargando…

Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand

PURPOSE: Given the lack of economic evaluation study of molecular testing in Thailand, this study aimed to evaluate the cost-utility of molecular testing algorithms including Xpert MTB/RIF and the loop-mediated isothermal amplification (TB-LAMP) in the general population suspected of having pulmonar...

Descripción completa

Detalles Bibliográficos
Autores principales: Chitpim, Natthakan, Jittikoon, Jiraphun, Udomsinprasert, Wanvisa, Mahasirimongkol, Surakameth, Chaikledkaew, Usa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819700/
https://www.ncbi.nlm.nih.gov/pubmed/35140485
http://dx.doi.org/10.2147/CEOR.S350606
_version_ 1784646104910921728
author Chitpim, Natthakan
Jittikoon, Jiraphun
Udomsinprasert, Wanvisa
Mahasirimongkol, Surakameth
Chaikledkaew, Usa
author_facet Chitpim, Natthakan
Jittikoon, Jiraphun
Udomsinprasert, Wanvisa
Mahasirimongkol, Surakameth
Chaikledkaew, Usa
author_sort Chitpim, Natthakan
collection PubMed
description PURPOSE: Given the lack of economic evaluation study of molecular testing in Thailand, this study aimed to evaluate the cost-utility of molecular testing algorithms including Xpert MTB/RIF and the loop-mediated isothermal amplification (TB-LAMP) in the general population suspected of having pulmonary TB based on a societal perspective. METHODS: A hybrid decision tree Markov model using a 1-month cycle length was used to evaluate costs and outcomes of five TB diagnostic algorithms: 1) sputum smear microscopy (SSM) with culture and drug susceptibility testing (DST), 2) Xpert MTB/RIF add-on, 3) Xpert MTB/RIF initial, 4) TB-LAMP add-on, and 5) TB-LAMP initial during a lifetime period. All costs were calculated in 2021 Baht, and results were presented as an incremental cost-effectiveness ratio (ICER) for molecular testing compared with SSM with culture. One-way sensitivity and probability analyses were used to evaluate uncertainty input parameters. RESULTS: TB-LAMP was less expensive overall (6565 Baht) than Xpert MTB/RIF (7010 Baht) and SSM with culture (6845 Baht). Molecular testing was projected to improve quality adjusted life year (QALY) by 0.53 to 0.94 years. In comparison to SSM with culture and DST, providing an initial TB-LAMP test was the most preferred choice. Xpert MTB/RIF Initial had the lowest ICER (197 Baht per QALY gained), followed by TB-LAMP Add-on (993 Baht per QALY gained) and Xpert MTB/RIF Add-on (3940 Baht per QALY gained). One-way sensitivity analysis uncovered that sensitivity of TB-LAMP was greater than that of other parameters. CONCLUSION: Providing molecular testing including Xpert MTB/RIF and TB-LAMP as either initial or add-on test for TB diagnosis was more cost-effective than SSM with culture and DST in the general population with suspected pulmonary TB in Thailand. Our study could provide useful evidence to policymakers advocating for inclusion of molecular testing in the universal health coverage benefit package in Thailand.
format Online
Article
Text
id pubmed-8819700
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-88197002022-02-08 Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand Chitpim, Natthakan Jittikoon, Jiraphun Udomsinprasert, Wanvisa Mahasirimongkol, Surakameth Chaikledkaew, Usa Clinicoecon Outcomes Res Original Research PURPOSE: Given the lack of economic evaluation study of molecular testing in Thailand, this study aimed to evaluate the cost-utility of molecular testing algorithms including Xpert MTB/RIF and the loop-mediated isothermal amplification (TB-LAMP) in the general population suspected of having pulmonary TB based on a societal perspective. METHODS: A hybrid decision tree Markov model using a 1-month cycle length was used to evaluate costs and outcomes of five TB diagnostic algorithms: 1) sputum smear microscopy (SSM) with culture and drug susceptibility testing (DST), 2) Xpert MTB/RIF add-on, 3) Xpert MTB/RIF initial, 4) TB-LAMP add-on, and 5) TB-LAMP initial during a lifetime period. All costs were calculated in 2021 Baht, and results were presented as an incremental cost-effectiveness ratio (ICER) for molecular testing compared with SSM with culture. One-way sensitivity and probability analyses were used to evaluate uncertainty input parameters. RESULTS: TB-LAMP was less expensive overall (6565 Baht) than Xpert MTB/RIF (7010 Baht) and SSM with culture (6845 Baht). Molecular testing was projected to improve quality adjusted life year (QALY) by 0.53 to 0.94 years. In comparison to SSM with culture and DST, providing an initial TB-LAMP test was the most preferred choice. Xpert MTB/RIF Initial had the lowest ICER (197 Baht per QALY gained), followed by TB-LAMP Add-on (993 Baht per QALY gained) and Xpert MTB/RIF Add-on (3940 Baht per QALY gained). One-way sensitivity analysis uncovered that sensitivity of TB-LAMP was greater than that of other parameters. CONCLUSION: Providing molecular testing including Xpert MTB/RIF and TB-LAMP as either initial or add-on test for TB diagnosis was more cost-effective than SSM with culture and DST in the general population with suspected pulmonary TB in Thailand. Our study could provide useful evidence to policymakers advocating for inclusion of molecular testing in the universal health coverage benefit package in Thailand. Dove 2022-02-02 /pmc/articles/PMC8819700/ /pubmed/35140485 http://dx.doi.org/10.2147/CEOR.S350606 Text en © 2022 Chitpim et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Chitpim, Natthakan
Jittikoon, Jiraphun
Udomsinprasert, Wanvisa
Mahasirimongkol, Surakameth
Chaikledkaew, Usa
Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
title Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
title_full Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
title_fullStr Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
title_full_unstemmed Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
title_short Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand
title_sort cost-utility analysis of molecular testing for tuberculosis diagnosis in suspected pulmonary tuberculosis in thailand
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819700/
https://www.ncbi.nlm.nih.gov/pubmed/35140485
http://dx.doi.org/10.2147/CEOR.S350606
work_keys_str_mv AT chitpimnatthakan costutilityanalysisofmoleculartestingfortuberculosisdiagnosisinsuspectedpulmonarytuberculosisinthailand
AT jittikoonjiraphun costutilityanalysisofmoleculartestingfortuberculosisdiagnosisinsuspectedpulmonarytuberculosisinthailand
AT udomsinprasertwanvisa costutilityanalysisofmoleculartestingfortuberculosisdiagnosisinsuspectedpulmonarytuberculosisinthailand
AT mahasirimongkolsurakameth costutilityanalysisofmoleculartestingfortuberculosisdiagnosisinsuspectedpulmonarytuberculosisinthailand
AT chaikledkaewusa costutilityanalysisofmoleculartestingfortuberculosisdiagnosisinsuspectedpulmonarytuberculosisinthailand